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Table S1: Regulatory explanations of the term 'biosimilar' 
European Medicines 
Agency1 
A biosimilar is a biological medicinal product that contains a version of the 
active substance of an already authorised original biological medicinal product 
(reference medicinal product) in the EEA. Similarity to the reference medicinal 
product in terms of quality characteristics, biological activity, safety and 
efficacy based on a comprehensive comparability exercise needs to be 
established. 
 
U.S. Food & Drug 
Administration 2  
Biosimilar or biosimilarity means that ‘the biological product is highly similar 
to the reference product notwithstanding minor differences in clinically inactive 
components’ and that ‘there are no clinically meaningful differences between 
the biological product and the reference product in terms of the safety, purity, 
and potency of the product’.  
 
EEA- European Economic Area 
1 European Medicines Agency (2014) Guideline on similar biological medicinal products  
2 Section 7002(b) (3) of the Affordable Care Act, adding section 351(i) (2) of the Public Health Services Act 
Table S2: Comparability exercise to support major manufacturing process changes - details of clinical studies and 
extrapolated indications 
Product name 
(Active 
substance) 
Approved 
indications 
Nature of 
change 
Clinical data 
 
 
Extrapolated 
indication 
Ref 
Herceptin® 
(Trastuzumab) 
 
Early breast 
cancer 
 
Metastatic breast 
cancer 
New 
formulation for 
subcutaneous 
administration  
 
Clinical trials in 
HER2+ early 
breast cancer 
patients  
 
 
 
Extrapolation to 
metastatic setting 
[1] 
Aranesp® 
(Darbepoetin 
alfa) 
Anaemia 
associated with 
chronic kidney 
failure  
 
Anaemia in adult 
cancer patients 
receiving 
chemotherapy 
 
New master cell 
bank and new 
manufacturing 
technology 
Clinical trials in 
chronic kidney 
failure patients 
 
 
 
Extrapolation to  
cancer indication 
[1] 
Avonex® 
(Interferon beta-
1a) 
Multiple sclerosis 
 
 
Changes to 
master cell bank 
and 
manufacturing 
process after 
pivotal phase III 
trials 
PK data 
 
 
 
MS indication 
approved without 
new clinical 
efficacy trial 
[2, 3] 
PK; pharmacokinetic, MS; multiple sclerosis 
 
  
Table S3: Substitution of biological medicines in Australia - Details of reference biological medicines and their biosimilars 
listed on the Australian Pharmaceutical Benefits Scheme (August 2018) 
Substance Products Substitution 
permitted 
(‘a’ flag status 
granted by 
PBAC)*. 
Reason ‘a’ flag status not granted Ref 
Etanercept Enbrel® 
Brenzys® 
 
Yes N/A [4] 
Epoetin alfa 
Epoetin lambda 
Eprex® 
Novicrit® 
No  At time of authorisation Novicrit 
has restricted route of 
administration when compared to 
Eprex  
 
[4, 5] 
Filgrastim Neupogen® 
Nivestim® 
 
No  Absence of TGA statement that 
supports ‘a’ flagging 
 
[4, 6] 
Follitropin Alfa Gonal-f® 
Bemfola® 
No Substitution difficult from a 
practical perspective owing to 
differences in strengths, number of 
pens per pack and maximum 
quantities per brand 
 
[4, 7] 
Infliximab Remicade® 
Inflectra® 
Renflexis® 
 
Yes N/A [4] 
Pegfilgrastim Neulasta®** 
Ristempa®** 
 
Yes* N/A [4] 
Somatropin Genotropin® 
Omnitrope® 
 
No  No details provided on PBAC 
website 
[4] 
*’Brand equivalents are accompanied by an ‘a’ flag on the Pharmaceutical Benefits Schedule.  An ‘a’ flagged medicine 
may be substituted by a pharmacist at the point of dispensing. 
**Neulasta and Ristempa are not biosimilars but are the same products with different brand names  
PBAC, Pharmaceutical Benefits Advisory Committee; TGA, Therapeutic Goods Administration 
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